New Drug Approvals

Home » Korea » Besifovir, бесифовир , بيسيفوفير , 贝西福韦 ,

Besifovir, бесифовир , بيسيفوفير , 贝西福韦 ,

Advertisements
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Blog Stats

  • 2,099,760 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,221 other followers

add to any

Share
Advertisements

Besifovir.svg

ChemSpider 2D Image | Besifovir | C10H14N5O4PBesifovir.png

Besifovir

  • Molecular FormulaC10H14N5O4P
  • Average mass299.223 Da
  • UNII-4PLG22CQUU
Phosphonic acid, [[[1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]- [ACD/Index Name]
бесифовир [Russian] [INN]
بيسيفوفير [Arabic] [INN]
贝西福韦 [Chinese] [INN]
((1-((2-Amino-9H-purin-9-yl)methyl)cyclopropoxy)methyl)phosphonic acid
[({1-[(2-Amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]phosphonic acid
{1-[(2-AMINOPURIN-9-YL)METHYL]CYCLOPROPOXY}METHYLPHOSPHONIC ACID
441785-25-7 [RN]

Besifovir (INN) is an investigational medication to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir.[2]

Image result for BESIFOVIR

Besifovir dipivoxil maleate

CAS:1039623-01-2, Propanoic acid, 2,2-dimethyl-, 1,1′-[[[[[1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]phosphinylidene]bis(oxymethylene)] ester, (2Z)-2-butenedioate (1:1)

Molecular Formula C22 H34 N5 O8 P . C4 H4 O4
 Molecular Weight 643.58
 Highest Phase Launched – 2017, korea

Besifovir dipivoxil maleate

Besifovir, also known as ANA-380; LB-80380; PMCDG dipivoxil, is a reverse transcriptase inhibitor potentially for treatment of hepatitis B infection. LB80380 is a prodrug and an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated.

str1

CAS 441785-26-8
Chemical Formula: C22H34N5O7P
Molecular Weight: 511.5158

Besifovir; ANA-380; AN-380; ANA 380; LB-80380; LB 80380; LB80380; PMCDG dipivoxil.

IUPAC/Chemical Name: ((((1-((2-amino-9H-purin-9-yl)methyl)cyclopropoxy)methyl)phosphanediyl)bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate)

Image result for BESIFOVIR

Ildong Pharma to release 1st chronic hepatitis B treatment next month
  • By Constance Williams
  • Published 2017.10.26 16:51
  • Updated 2017.10.26 19:12

Ildong Pharmaceutical will release its first chronic hepatitis B therapy of nucleotide series “Besivo” as an insurance benefit drug next month, the company said Thursday.

Besivo is a treatment for chronic hepatitis B based on the nucleotide sequence, which is composed of besifovir.

The price of the insurance is 3,403 won ($3.02) per tablet, which was recently confirmed by the Ministry of Health and Welfare보건복지부. Insurance benefits also cover El-carnitine medications used in combination, and the insurance price for one tablet (330mg) is 111 won.

According to the results of clinical trials, Besivo has demonstrated comparable levels of therapeutic efficacy in a randomized, double-blind trial compared with traditional therapies such as Entecavir (trade name: Baraclude) and Tenofovir (trade name: Viread). Besivo improved the prospects as a valid option for the treatment of chronic hepatitis B by improving the side effects found in the existing medications.

In particular, further analysis of clinical trials has shown that typical side effects such as decreased renal function and decreased bone density, which was a problem in the existing Tenofovir. Knodell necro-inflammatory score, was also superior to the control group regarding the histological improvement of the liver.

For the deterioration of renal function, the rate of increase in serum creatinine — a test that measures kidney function – was significantly lower than that of Tenofovir.

With the case of measuring bone mineral density, the proportion of patients showing bone turnover increased and the percentage of patients showing average bone mineral density decreased in the case of Tenofovir. With Besivo, the rate of patients with bone loss decreased, and the percentage of patients with average bone mineral density increased.

Ildong Pharma 일동제약 (CEO: Yun Woong-sup윤웅섭) plans to go on marketing with the idea that Besivo is a domestic drug that secures safety by improving side effects of existing medicines as well as treatment effects that are comparable to that of foreign pharmaceutical companies. In particular, the company expects the cost of pharmaceuticals to be 25 percent lower than that of Viread, the leading drug in the market.

“Due to the nature of chronic hepatitis B treatment for long-term use, safety is critical, and there are few side effects, so Besivo is highly valuable as a few nucleotide drugs existing in consideration of cross-resistance,” said Professor Ahn Sang-hoon안상훈 of Severance Hospital세브란스병원who participated in the clinical study.

“There is a strong competitive edge regarding the advantages of Besivo in connection with the entry into the Asian market, where the demand for therapeutic drugs is increasing as a major outbreak of hepatitis B,” he added.

Il Dong, under license from LG Life Sciences , has developed and launched Besivo (besifovir dipivoxil maleate), a phosphonate nucleoside inhibitor of HBV polymerase, for treating HBV infection. In October 2012, Il Dong was planning on seeking to outlicense the drug outside of Korea.

Besifovir dipivoxil maleate is a DNA polymerase inhibitor discovered and developed by LG Chem. The product was launched in Korea in 2017 by codeveloper ILDONG for the treatment of hepatitis B.

In April 2004, Anadys (acquired by Roche in 2011) obtained an exclusive license from LG Chem for the commercialization of LB-80380 worldwide excluding China, Korea, India and Southeast Asia. In August 2007, Anadys reported that it had discontinued development of LB-80380 and returned all rights to LG Chem in order to focus on other key compounds.

PAPER

A Novel Class of Phosphonate Nucleosides. 9-[(1-Phosphonomethoxycyclopropyl)methyl]guanine as a Potent and Selective Anti-HBV Agent

LG Life Sciences Ltd., R & D Park, 104-1 Moongi-dong, Yusung-gu, Daejeon 305-380, Korea
J. Med. Chem.200447 (11), pp 2864–2869
DOI: 10.1021/jm0305265
Publication Date (Web): April 16, 2004
Copyright © 2004 American Chemical Society

Abstract

Abstract Image

9-[1-(Phosphonomethoxycyclopropyl)methyl]guanine (PMCG, 1), representative of a novel class of phosphonate nucleosides, blocks HBV replication with excellent potency (EC50 = 0.5 μM) in a primary culture of HepG2 2.2.15 cells. It exhibits no significant cytotoxicity in several human cell lines up to 1.0 mM. It does not inhibit replication of human immunodeficiency virus (HIV-1) or herpes simplex virus (HSV-1) at 30 μM. Many purine base analogues of 1 also exhibit inhibitory activity against HBV, but at 30 μM, pyrimidine analogues do not. 1 is 4 times more potent than 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA), which was used as a positive control (EC50 = 2.0 μM). The characteristic cyclopropyl moiety at the 2‘-position of 1 was prepared by titanium-mediated Kulinkovich cyclopropanation. 1 was modified to give the orally available drug candidate, PMCDG Dipivoxil (2). Compound 2 exhibited excellent efficacy when administered at 5 mg per kg per day in a study with woodchucks infected with woodchuck hepatitis B virus (WHBV). Drug candidate 2 has successfully completed phase I clinical trials and is currently undergoing phase II clinical studies for evaluation of efficacy.

({1-[(2-Amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic Acid (PMCDG, 8).  (89.5% yield) as yellowish solids. The compound was recrystallized from water for X-ray crystallography. 1H NMR (400 MHz, DMSO-d6):  δ 0.92 (br q, 4H), 3.76 (d, J = 12.0 Hz, 2H), 4.33 (s, 2H), 8.0 (br s, 2H), 8.74 (s, 1H), 9.00 (s, 1H). 13C NMR (100 MHz, DMSO-d6):  δ 11.6 (2C), 45.9, 62.9 (d, J = 15.0 Hz), 63.0 (d, J = 161 Hz), 125.6, 139.1, 149.8, 154.2, 157.1. HRMS (MH+):  300.0862 calcd for C10H14N5O4P, found 300.0872. Anal. (C10H14N5O4P·H2O) C, H, N.

({1-[(2-Amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methylphosphonic Acid Dipivoxyl (PMCDG Dipivoxyl, 2). (38.5% yield) as white solids. mp:  92 °C. 1H NMR (400 MHz, CDCl3):  δ 0.89 (br t, 2H), 1.06 (br t, 2H), 1.21 (s, 18H), 3.97 (d, J = 10.0 Hz, 2H), 4.23 (s, 2H), 5.0 (br s, 2H), 5.62 (m, 2H), 8.01 (s, 1H), 8.68 (s, 1H). 13C NMR (100 MHz, CDCl3):  δ 12.3 (2C), 26.7 (6C), 38.6 (2C), 46.0, 62.1 (d, J = 170 Hz), 64.1 (d, J = 15.0 Hz), 81.6 (d, J = 6.0 Hz, 2C), 127.6, 143.0, 149.4, 153.4, 158.9, 176.6 (2C). HRMS (MH+):  528.2223 calcd for C10H14N5O4P, found 528.2233. Anal. (C22H34N5O8P) C, H, N.

PATENT

Besifovir dipivoxil’s product PAT, WO2057288

https://encrypted.google.com/patents/WO2002057288A1?cl=en

(a) CH3CH2MgBr, Ti(Oi-Pr)4 (0.25 equiv), THF, 0 °C to 25 °C, 10 h;

(b) BrCH2P(O)(Oi-Pr)2, LiOt-Bu, LiI (cat.), DMF, THF, 60 °C, 4 h;

(c) NH4F, MeOH, reflux, 10 h;

CONTD……….

(d) MsCl, TEA, MDC, 0 °C to 25 °C; (e) 6-chloroguanine, NaH, DMF, 80 °C, 4 h; (f) H2, 5% Pd on C, THF, 1 atm, 18 h; (g) TMSBr, MDC, reflux, 18 h; (h) 2 N HCl, reflux, 6 h; (i) chloromethyl pivalate, TEA, 1-methyl-2-pyrrolidinone, 25 °C, 48 h.

Inventors Jong-Ryoo ChoiJeong-Min KimKee-Yoon RohDong-Gyu ChoJae-Hong LimJae-Taeg HwangWoo-Young ChoHyun-Sook JangChang-Ho LeeTae-Saeng ChoiChung-Mi KimYong-Zu KimTae-Kyun KimSeung-Joo ChoGyoung-Won KimLess «
Applicant Lg Life Sciences Ltd.

WO 2002057288

PATENT

WO-2018016795

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018016795&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=FullText

Novel crystalline polymorphic forms of 3-[({1-[(2-amino-9H-furyn-9-yl) methyl] cyclopropyl}oxy) methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate orotate (Besifovir dipivoxil), a process for its preparation, and composition comprising the salt for treating viral infections are claimed.

[({1 – [(2-amino -9 H -purin-9-yl) methyl] cyclopropyl} oxy) methyl] -8,8- dimethyl-3,7-dioxo Orotate of bis-4,6-trioxa-3? 5 -phosphonon-1-yl-pivalate (besifovir dipivoxil), a process for its preparation and a pharmaceutical composition comprising said salt Lt; / RTI & gt;
[Formula 1]
The free compound of the above formula (1) is a novel anti-viral substance disclosed in Korean Patent No. 0441638 and WO 02/057288. However, these compounds are very unstable against heat and moisture, and are difficult to be used as raw materials for pharmaceutical compositions.

[6]
In Korean Patent No. 0935904, various pharmaceutically acceptable salts have been prepared to solve such problems. In this process, some of the salts have proven to be difficult to obtain as crystalline solids and have been successfully obtained as crystalline solids only in the case of maleate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate and ethanesulfonate, Bessyfovir dipivicum maleic acid mono-salt is remarkably excellent in thermal stability compared to its free compounds and other salts.

[7]
However, bissipovid epipixyl maleate is very unstable at high temperatures of 100 ° C or higher and is mostly decomposed in 6 hours and still insufficient in stability. In case of contact, it may cause severe irritation accompanied by redness, pain, Due to the characteristics of maleic acid, symptoms similar to those of conjunctivitis or acute exposure may occur during manufacture (see the Toxicological Information of the Food and Drug Administration), and caution is also required for safety.
FIG.5 shows the infrared spectroscopy (FT-IR) of the bisphosphonite pyrophosphorate of Example 1. Fig.
6 shows the 1 H nuclear magnetic resonance spectrum (NMR) of the bisporovir diplyl orthoate of Example 1. Fig.
The free compound of the above formula (1) is a novel anti-viral substance disclosed in Korean Patent No. 0441638 and WO 02/057288. However, these compounds are very unstable against heat and moisture, and are difficult to be used as raw materials for pharmaceutical compositions.

[6]
In Korean Patent No. 0935904, various pharmaceutically acceptable salts have been prepared to solve such problems. In this process, some of the salts have proven to be difficult to obtain as crystalline solids and have been successfully obtained as crystalline solids only in the case of maleate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate and ethanesulfonate, Bessyfovir dipivicum maleic acid mono-salt is remarkably excellent in thermal stability compared to its free compounds and other salts.

[7]
However, bissipovid epipixyl maleate is very unstable at high temperatures of 100 ° C or higher and is mostly decomposed in 6 hours and still insufficient in stability. In case of contact, it may cause severe irritation accompanied by redness, pain, Due to the characteristics of maleic acid, symptoms similar to those of conjunctivitis or acute exposure may occur during manufacture (see the Toxicological Information of the Food and Drug Administration), and caution is also required for safety.

References

  1. Jump up^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). “ATC/DDD Classification (FINAL): New ATC 5th level codes”. WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
  2. Jump up^ Lin CL, Yang HC, Kao JH (4 January 2016). “Hepatitis B virus: new therapeutic perspectives”Liver Int. John Wiley & Sons Ltd. 36(Supplement S1): 85–92. doi:10.1111/liv.13003PMID 26725903.
Patent ID

Patent Title

Submitted Date

Granted Date

US7723319 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
2010-01-07
2010-05-25
US7605147 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
2006-12-28
2009-10-20
US7157448 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
2004-04-01
2007-01-02
US2006052346 Nucleoside phosphonate derivatives useful in the treatment of HIV infections
2006-03-09
Besifovir
Besifovir.svg
Clinical data
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C10H14N5O4P
Molar mass 299.223022 g/mol
3D model (JSmol)

////////////Besifovir, бесифовир , بيسيفوفير , 贝西福韦 , ANA-380, AN-380, ANA 380, LB-80380, LB 80380, LB80380, PMCDG dipivoxil

C1CC1(CN2C=NC3=CN=C(N=C32)N)OCP(=O)(O)O

NC1=NC=C2N=CN(CC3(OCP(OCOC(C(C)(C)C)=O)OCOC(C(C)(C)C)=O)CC3)C2=N1

Advertisements

1 Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,221 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: